Breast cancer is the second most common cancer in women with approximately 522,000 deaths annually worldwide. microRNAs have recently been studied as potential biomarkers that regulate gene expression and are involved in tumorigenesis. Here we evaluated circulating miR-221 and miR-222 as potential biomarkers for breast cancer by quantitative reverse transcription PCR using blood plasma of 30 healthy controls and 30 breast cancer patients. The TNM stage on circulating miR-221 and miR-222 was also investigated. Circulating miR-221 and miR-222 were significantly up-regulated in breast cancer patients compared to those in healthy controls (P < 0.0022 and P = 0.0058, respectively). Furthermore, the relative expression level of circulating miR-221 in patients with stage III breast cancer was higher than in those with stage I and II. Taken together, we have shown circulating miR-221 and miR-222 could be useful biomarkers for the screening of breast cancer patients.
Breast cancer is the most frequently occurring disease in females and the second leading cause of death worldwide (Siegel et al., 2018) . According to the World Health Organization (WHO), approximately 522,000 women die each year from breast cancer (Ferlay et al., 2015) . Current methods used to diagnose breast cancer such as mammography, computed tomography (CT), and magnetic resonance imaging (MRI) have been hindered by the cost and expertise needed.
In addition, tumor serum markers such as carbohydrate antigen 15-3 (CA15-3) and carcinoembryonic antigen (CEA) are nonspecific and have limited sensitivity and specificity (Duffy, 1999; Ng et al., 2014) . Therefore, it is necessary to discover new non-invasive biomarkers for the diagnosis of breast cancer. with miR-16 as an endogenous control (Pfaffl et al., 2002 and miR-222 in breast cancer patients were significantly higher than those in the healthy controls (P < 0.0022 and P = 0.0058, respectively) ( (Fig. 2A) . For miR-222, there also was a significant difference between stage II and the healthy controls (P = 0.0084) (Fig. 2B ).
Brief Communication
Many recent studies have reported blood-based biomarkers for diagnosing breast cancer, such as circulating tumor cells as biomarkers, such as stability during pH changes, freezethaw cycles, and extended storage (Mitchell et al., 2008; Yu et al., 2011) . In this study, circulating miR-221 and miR-222
were potential biomarkers showing 2.87-fold and 2.44-fold higher expression for breast cancer patients compared with healthy controls, respectively.
In this study, some healthy controls were shown high expression of miR-221 and miR-222 or some patients with stage III were shown low expression of miR-221 and miR-222. The reason for discrepancies of miR-221 and miR-222 expression in healthy controls and breast cancer patients was that microRNAs regulate multi-genes rather than a single gene. For example, miR-221/222 was associated with oncogenic process regulating tumor suppressor gene PTEN (Li et al., 2016) . Also, miR-221/222 was associated with inflammatory immune response regulating peroxisome proliferatoractivated receptor-γ coactivator-1α (Song et al., 2017) .
There are limitations to our study. First, a small number of samples were included. Therefore, it is necessary to conduct further research using a larger number of samples from breast cancer patients at various stages to demonstrate the utility of circulating miR-221 and miR-222 for breast cancer screening and diagnosis. Second, we only included breast cancer patients with cancer stage I-III. Further study with stage IV patients is needed to investigate the expression of circulating miR-221 and miR-222 with breast cancer stage IV patients.
In conclusion, expression levels of miR-221 and miR-222 in plasma were significantly higher for breast cancer patients than for healthy controls. Notably, miR-221 in patients with stage III breast cancer was higher than in those with stage I and II. Taken together, circulating miR-221 and miR-222 can serve as potential non-invasive biomarkers for breast cancer screening and diagnosis.
